Bin Yang

52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial

BACKGROUND: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVES: To describe efficacy and safety outcomes through Week 52. METHODS: In this multicentr...

Social determinants of health and lifestyle in the progression of degenerative bone and joint diseases: a prospective multi-state analysis

Abstract Aims The role of social determinants of health (SDOH) in the progression of degenerative bone and joint diseases (DBJDs) - from initial onset to multimorbidity and mortality - remains unclear. We aimed to assess the associations of SDOH with DBJDs progression, examine th...